Ronan C OHagan
Overview
Explore the profile of Ronan C OHagan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jenkins K, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, et al.
J Immunother Cancer
. 2024 Jan;
11(12).
PMID: 38164757
Introduction: The clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adverse events, especially when ipilimumab is used in combination with anti-PD-(L)1...
2.
Patel E, Malkova N, Crowe D, Pederzoli-Ribeil M, Fantini D, Fanny M, et al.
Mol Cancer Ther
. 2023 Nov;
23(4):421-435.
PMID: 38030380
IL12 is a proinflammatory cytokine, that has shown promising antitumor activity in humans by promoting the recruitment and activation of immune cells in tumors. However, the systemic administration of IL12...
3.
McKelvey B, Berk A, Chin L, Hudgens S, Kudel I, OHagan R, et al.
JCO Clin Cancer Inform
. 2023 Feb;
7:e2200161.
PMID: 36821804
Purpose: Using patient-reported outcomes (PROs) provides important insights from the patient's perspective and can be valuable to monitor and manage treatment-related adverse events during cancer treatment. Additionally, the digital administration...
4.
Allali-Hassani A, Szewczyk M, Ivanochko D, Organ S, Bok J, Ho J, et al.
Nat Commun
. 2019 Dec;
10(1):5759.
PMID: 31848333
PRDM9 is a PR domain containing protein which trimethylates histone 3 on lysine 4 and 36. Its normal expression is restricted to germ cells and attenuation of its activity results...
5.
Celano S, Yco L, Kortus M, Solitro A, Gunaydin H, Scott M, et al.
iScience
. 2019 May;
15:109-118.
PMID: 31048145
In cancer, autophagy is upregulated to promote cell survival and tumor growth during times of nutrient stress and can confer resistance to drug treatments. Several major signaling networks control autophagy...
6.
Martin K, Celano S, Solitro A, Gunaydin H, Scott M, OHagan R, et al.
iScience
. 2018 Oct;
8:74-84.
PMID: 30292171
In response to stress, cancer cells generate nutrients and energy through a cellular recycling process called autophagy, which can promote survival and tumor progression. Accordingly, autophagy inhibition has emerged as...
7.
Muller S, Ackloo S, Arrowsmith C, Bauser M, Baryza J, Blagg J, et al.
Elife
. 2018 Apr;
7.
PMID: 29676732
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these...
8.
Arrowsmith C, Audia J, Austin C, Baell J, Bennett J, Blagg J, et al.
Nat Chem Biol
. 2015 Oct;
11(11):887.
PMID: 26485080
No abstract available.
9.
Arrowsmith C, Audia J, Austin C, Baell J, Bennett J, Blagg J, et al.
Nat Chem Biol
. 2015 Jul;
11(8):536-41.
PMID: 26196764
No abstract available.
10.
Williams S, Kuznicki A, Andrade P, Dolinski B, Elbi C, OHagan R, et al.
Cancer Cell Int
. 2015 Feb;
15(1):14.
PMID: 25685067
Background: Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive to PARP inhibition. Microsatellite instability (MSI) accounts for 10-15% of...